TLT Broke Out And Should Continue Higher
The iShares 20+ Year Treasury Bond ETF (NASDAQ:TLT) is finally breaking out and making a higher high for 2024. TLT shares are appreciating along
ETFs are on pace to break record annual inflows, but this wild card could change it all
Exchange-traded fund inflows have already topped monthly records in 2024, and managers think inflows could see an impact from the money market fund boom
CIA director saw ‘genuine risk’ of Russia using tactical nuclear weapons early in Ukraine war
CIA Director William Burns believed there was a real risk in the fall of 2022 that Russia could use nuclear weapons on the battlefield
Crown Castle: Lower Rates Offer Tailwind, But Competitive And Refinancing Risks Mount
Interest rate-sensitive stocks are among the few that may perform well in a bear market, particularly those that have lost value as interest rates
Chips get crushed, and clues in the jobs report for Modelo brewer Constellation Brands
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour
RFK Jr. is dropped from ballots in North Carolina and Michigan by appeals courts
Former independent presidential candidate Robert F. Kennedy Jr. will not appear on ballots in North Carolina and Michigan, appeals courts ruled in two separate
GoDaddy Stock: Growth At A Reasonable Price, But Website Demand May Slow (NYSE:GDDY)
GoDaddy (NYSE:GDDY) has broken out into a high-momentum rally as investors have caught wind of its strong historical income growth and have renewed competitive
7-Eleven’s parent company rejects takeover proposal, says offer ‘grossly undervalues’ company
Seven & i Holdings has rejected the takeover offer from Canadian convenience store operator Alimentation Couche-Tard, saying the offer “is not in the best
‘Economic refugees’ flee from New Zealand as cost-of-living crisis deepens
Once recognized by the world as a picturesque and progressive safe haven, New Zealand’s frail economy has pushed many of its citizens to leave
Verastem’s Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity (NASDAQ:VSTM)
Verastem, Inc. (NASDAQ:VSTM) is a clinical-stage biopharmaceutical company that develops cancer treatments targeting the RAS/MAPK pathway. This cell growth modulator is useful for pancreatic,
Most Read
